Eli Lilly hits $1 trillion market cap as Medicare expands GLP-1 drug access
Eli Lilly's stock surged past $1 trillion valuation after Medicare signaled broader coverage of GLP-1 obesity drugs, expanding addressable market for the pharma
Ad-hoc-news.de · +14 outlets
Novo Nordisk Wegovy clears higher-dose FDA approval; obesity drug portfolio under close watch
Novo Nordisk won FDA approval for a higher-dose formulation of Wegovy while earnings outlook and momentum in obesity drugs kept shares under investor scrutiny a
Stocktwits · +14 outlets
Pfizer posts lung cancer trial setback while advancing obesity drug strategy with monthly GLP-1
Pfizer shares declined on disappointing lung cancer trial results, even as the company made its largest obesity bet with a monthly injectable GLP-1 candidate.
MSN · +3 outlets
Moderna surges 13 percent on flu vaccine FDA view and in vivo CAR-T cell therapy progress
Moderna stock jumped on unexpected FDA support for its mRNA-based flu shot and breakthrough results in in vivo CAR-T cell therapy development.
Blockonomi · +1 outlets
GLP-1 manufacturing boom exposes capacity crunch at Indian pharma firms
India's pharmaceutical manufacturers face significant capacity constraints as global demand for GLP-1 obesity drugs surges, while Indian biotech executives warn
Business Standard · +2 outlets
Viridian Lumvoa becomes first FDA-approved thyroid eye disease treatment
Viridian's Lumvoa won FDA clearance as the first approved therapy for thyroid eye disease, with shares jumping 6 percent on the milestone approval.
Investing.com UK · +8 outlets
Eli Lilly EU clearance for CLL drug, GLP-1 access win drives stock 10 percent rally
Eli Lilly gained European Committee for Medicinal Products approval for Jaypirca in chronic lymphocytic leukemia alongside Medicare GLP-1 expansion news.
simplywall.st · +1 outlets
US targets German drug makers on pricing as trade tensions escalate
Washington is investigating Swiss and German pharmaceutical companies on drug pricing practices, part of escalating US trade pressure on global pharma pricing d
dw.com · +12 outlets
Gilead wins FDA approval for Trodelvy in triple-negative breast cancer
Gilead Sciences secured FDA approval for Trodelvy in triple-negative breast cancer, expanding the oncology drug's labeling.
Yahoo Finance · +14 outlets
State lawmakers target PBM pricing practices to lower drug costs for patients
States are pursuing legislation to regulate pharmacy benefit managers' pricing practices while federal officials consider 340B program reforms.
The Tribune-Democrat · +14 outlets
Johnson & Johnson exits obesity drug race to focus on cancer drug leadership
Johnson & Johnson abandoned its obesity drug development program to concentrate resources on expanding its oncology portfolio and market position.
Sahm · +1 outlets
AbbVie gains FDA approval for Skyrizi in children with psoriasis
AbbVie obtained FDA clearance to extend Skyrizi use to pediatric psoriasis patients, broadening the drug's approved population.
GuruFocus · +7 outlets
Capricor Deramiocel advances toward FDA decision with July 29 advisory committee hearing
Capricor Therapeutics' Deramiocel cell therapy for Duchenne muscular dystrophy is set for FDA advisory committee review on July 29.
GlobeNewswire · +3 outlets
India's CDSCO issues guidance on drug approvals, obesity drug marketing oversight
India's Central Drugs Standard Control Organisation issued new guidance on modified-release drug approvals and issued advisory against misleading GLP-1 obesity
The Hindu · +14 outlets
Race heats up for next-generation obesity drugs as GLP-1 competition intensifies
Multiple companies are advancing new obesity drug candidates to compete in the rapidly growing GLP-1 and next-generation weight-loss market.
Gizmodo · +14 outlets
CVS Health launches integrated GLP-1 weight loss service plan for employer benefits
CVS Health introduced a comprehensive service offering combining GLP-1 obesity drugs with counseling and monitoring for employer health plans.
NAI500 · +14 outlets
Replimune receives FDA review pathway for advanced melanoma immunotherapy
Replimune and Regeneron Partner 1 both advanced in FDA review processes for advanced melanoma treatments using immunotherapy approaches.
GuruFocus · +14 outlets
Ibrx rally continues as Trump diplomacy aids cancer drug development; Saudi approval secured
Ibrx shares extended gains after chairman credited Trump administration diplomacy with accelerating cancer drug progress and the company won Saudi regulatory ap
Stocktwits